Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.

@article{Shields2004ChemoreductionFR,
  title={Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.},
  author={Carol L Shields and Arman Mashayekhi and Jacqueline Cater and Abdallah E. Shelil and Anna T. Meadows and Jerry A. Shields},
  journal={Transactions of the American Ophthalmological Society},
  year={2004},
  volume={102},
  pages={35-44; discussion 44-5}
}
PURPOSE To evaluate individual tumor control following chemoreduction for retinoblastoma. METHODS Prospective nonrandomized single-center case series of 457 retinoblastomas managed with six cycles of chemoreduction (vincristine, etoposide, and carboplatin). The tumors were then managed with chemoreduction alone (group A) or chemoreduction combined with thermotherapy (group B), cryotherapy (group C), or both thermotherapy and cryotherapy (group D). The main outcome measure was development of… CONTINUE READING